Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (FLAIR)

Phase 3, previously untreated CLL: MRD-guided ibrutinib-venetoclax vs FCR (n=523). After 2 months of ibrutinib, venetoclax was added for up to 6 years, with duration guided by MRD. At median 43.7 months, progression or death occurred in 12 vs 75 patients (HR 0.13, 95% CI 0.07-0.24, P<0.001); death in 9 vs 25 (HR 0.31, 95% CI 0.15-0.67). At 3 years, 58.0% in the I+V group had stopped therapy because of undetectable MRD. After 5 years of I+V, 65.9% had undetectable MRD in BM and 92.7% in PB. Level 1 (randomized MRD-guided duration).

N Engl J MedPubMed 38078508